Bhabha Atomic Research Centre, Mumbai develops Eye Cancer therapy

• Feb 21 CA
• Jan 21 CA
• Dec 20 CA
• Nov 20 CA
• Oct 20 CA
• Sep 20 CA
• Aug 20 CA
• Jul 20 CA
• Jun 20 CA
• May 20 CA

Daily Current Affairs Article 31th December 2020: Bhabha Atomic Research Centre (BARC) Mumbai has developed Eye Cancer therapy in the form of the first indigenous Ruthenium 106 Plaque for treatment of Ocular Tumours.

The handling of plaque is very convenient for the Surgeon and it has been acknowledged to be at par with the international standards.

So far the BARC plaques made in India through the Department of Atomic Energy have been used for seven cases for Ocular Cancer.

Ocular tumours are tumours inside the eye. They are collections of cells that grow and multiply abnormally and form masses.

Ruthenium-106 is a radioactive form of the rare heavy metal ruthenium, which is a "platinum group" metal similar to platinum.

Ruthenium-106 is produced from the fission or splitting of uranium-235, the type of uranium used in nuclear fission reactors, so it's found in spent nuclear fuel.

It's used in medicine for cancer radiation therapy, especially for eye and skin tumours. It's also used in radioisotope thermoelectric generators that power satellites.